Forte Biosciences' Future In Doubt After Only Product Fails
Microbiome Product Missed Phase II Endpoints
Executive Summary
Forte Biosciences’ attempts to use a new approach to treating inflammatory skin disease using a topical live biotherapeutic, FB-401, have come to a crashing halt at Phase II. Where the company goes next remains to be seen.